Pharma News: Label Change to Bydureon, Inspire Trial Fails Monday, March 15, 12:41 PM ET
The Food and Drug Administration is demanding clarifications on the labeling and manufacturing process for Bydureon, a new drug candidate of Amylin Pharmaceuticals (AMLN), Eli Lilly (NYSE:LLY) and Alkermes (NASDAQ:ALKS).
The FDA would like changes made to clarify the product labeling and asked questions about the drug’s manufacturing process.
Bydureon is a once weekly form of the Type II diabetes drug Byetta, which already has annual sales of $700 million.
The drug has been developed by Amylin and Lilly, and uses controlled release technology from Alkermes.
The companies will respond to the FDA’s requests within a few weeks.
Amylin shares are trading over 8 percent Monday, while Lilly shares are trading about flat.
Also in the pharma industry this morning, Inspire Pharmaceuticals (ISPH) said today two Phase II clinical trials of its blepharitis drug Azasite failed to meet primary endpoints. Blepharitis is inflammation of the eyelids.
Upcoming Dividend Run For APOG? Monday, January 19, 11:43 AM ET, by Market News Video Staff This morning a "Potential Dividend Run Alert" went out for Apogee Enterprises Inc (NASD: APOG), ...
ELVA Crosses Above Average Analyst Target Monday, January 19, 11:42 AM ET, by Market News Video Staff In recent trading, shares of Electrovaya Inc (ELVA) have crossed above the average analyst 12-month ...
PMT Crosses Above Average Analyst Target Monday, January 19, 11:42 AM ET, by Market News Video Staff In recent trading, shares of Pennymac Mortgage Investment Trust (PMT) have crossed above the average ...
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.2%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.2%.
Free Email Alerts By Stock:
Friday 1/16 Insider Buying Report: MU, NEWT
Thursday 1/15 Insider Buying Report: IMRX, DLPN
Thursday 1/15 Insider Buying Report: ACVA, GRX
Nasdaq 100 Movers: CEG, MU
S&P 500 Movers: VST, MU
Dow Movers: CRM, NVDA
S&P 500 Analyst Moves: IDXX
S&P 500 Analyst Moves: PANW
S&P 500 Analyst Moves: APH
Friday Sector Laggards: Paper & Forest Products, Packaging & Containers
Friday Sector Leaders: Construction, Semiconductors
Thursday Sector Laggards: Drugs, Biotechnology Stocks
Friday's ETF with Unusual Volume: JXI
Friday's ETF Movers: URA, KWEB
PGX, DAMD: Big ETF Outflows
Daily Dividend Report: TXN,GHC,QCOM,COST,IBCP
Daily Dividend Report: PPG,ADP,SPGI,SKT,AM
Daily Dividend Report: O,UNF,KALU,ADC,LH
Fed Tapers Bond Buying
Nonfarm payroll Employment Up 175,000 in February
Initial Claims Decrease, Productivity 1.8% Annual Rate Increase in Q4
Weekly Market Wrap: August 14, 2015
Weekly Market Wrap: August 7, 2015
Weekly Market Wrap: July 31, 2015
Week Ahead Market Report: June 8, 2015
Week Ahead Market Report: May 18, 2015
Week Ahead Market Report: May 4, 2015